Inventory

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Inventory

(4)Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of December 31, 2022 and 2021 consist of the following:

In thousands	December 31, 2022		December 31, 2021
Raw materials	$	126,391	$	107,695
Work in process		52,297		41,965
Finished goods		213,664		206,270
Inventory	$	392,352	$	355,930

The Company classifies inventory as long-term when consumption of the finished goods and work in process inventory are expected beyond the normal operating cycle. As of December 31, 2022 and 2021, we had $163.6 million and $121.3 million of Long-term inventory, respectively.